292 studies found for:    "Alkylating Agents" | updated in the last 30 days
Show Display Options
Rank Status Study
1 Recruiting Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor
Conditions: Sarcoma;   Desmoplastic Small Round Cell Tumor (DSRCT)
Intervention: Drug: irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator
2 Recruiting Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence
Condition: Solid Tumor
Interventions: Drug: Bevacizumab;   Drug: Cyclophosphamide;   Drug: Valproic Acid;   Drug: Temsirolimus
3 Recruiting Ph 3 Trial of Blinatumomab vs Investigator's Choice of Chemotherapy in Patients With Relapsed or Refractory ALL
Condition: Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Interventions: Drug: Blinatumomab;   Drug: Standard of Care Chemotherapy
4 Active, not recruiting Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Capecitabine;   Drug: Bendamustine
5 Completed A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)
Condition: Lymphoblastic Leukemia, Acute, Childhood
Intervention: Drug: Clofarabine incorporated into a 5-drug regimen
6 Active, not recruiting Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Bendamustine;   Drug: Rituximab;   Drug: Lenalidomide
7 Active, not recruiting A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Patients With HER2-Positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: FEC: 5-Fluorouracil/epirubicin/cyclophosphamide;   Drug: carboplatin;   Drug: docetaxel;   Drug: pertuzumab;   Drug: trastuzumab;   Drug: trastuzumab [Herceptin]
8 Recruiting INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Carboplatin;   Drug: Pegylated Lipoxomal Doxorubicin (PLD);   Drug: Trabectedin
9 Recruiting Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Previously Treated Myelodysplastic Syndromes;   Secondary Acute Myeloid Leukemia
Interventions: Drug: clofarabine;   Drug: melphalan;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis;   Drug: tacrolimus;   Drug: sirolimus
10 Recruiting T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
Condition: Metastatic Cancers Other Than Melanoma That Express ESO Antigen
Interventions: Biological: Anti-NY ESO-1 mTCR PBL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Aldesleukin
11 Recruiting Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
Conditions: Leukemia;   Lymphoma
Interventions: Drug: Rituximab;   Drug: 111In Ibritumomab;   Procedure: Planar Scintigraphy Imaging;   Drug: 90Y IbritumomabTiuxetan;   Drug: Fludarabine;   Drug: Bendamustine;   Drug: Thymoglobulin;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Mycophenolate;   Drug: G-CSF;   Procedure: Stem Cell Transplantation
12 Recruiting Cord Blood Natural Killer Cells for Myeloma
Condition: Myeloma
Interventions: Drug: Lenalidomide;   Drug: Melphalan;   Procedure: NK Cell Infusion;   Procedure: Stem Cell Infusion;   Drug: G-CSF
13 Recruiting Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS)
Conditions: Chronic Fatigue Syndrome (CFS);   Myalgic Encephalomyelitis (ME)
Intervention: Drug: Cyclophosphamide
14 Recruiting Treatment of Rapid Onset Obesity, Hypoventilation, Hypothalamic Dysfunction, and Autonomic Dysregulation (ROHHAD )
Condition: ROHHAD Syndrome
Intervention: Drug: Cyclophosphamide
15 Active, not recruiting S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer
Condition: Breast Cancer
Interventions: Biological: bevacizumab;   Biological: pegfilgrastim;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel albumin-stabilized nanoparticle formulation
16 Recruiting Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
Conditions: Stage II Contiguous Adult Diffuse Large Cell Lymphoma;   Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
17 Recruiting Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Velcade;   Drug: Cyclophosphamide;   Drug: Revlimid
18 Recruiting A Comparison of Continuous Avastin (Bevacizumab) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Patients With Glioblastoma
Condition: Glioblastoma
Interventions: Radiation: Radiotherapy;   Drug: SOC;   Drug: bevacizumab [Avastin];   Drug: lomustine;   Drug: placebo;   Drug: temozolomide
19 Recruiting Preoperative Chemoradiation for Glioblastoma
Condition: Glioblastoma
Interventions: Drug: Temozolomide;   Radiation: partial brain irradiation;   Procedure: stereotactic biopsy of brain tumor;   Procedure: craniotomy and tumor resection
20 Recruiting Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores
Conditions: Breast Neoplasms;   Breast Cancer;   Cancer of the Breast
Interventions: Drug: Docetaxel with Cytoxan;   Drug: Dexamethasone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years